These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7319296)

  • 1. Quantitation of chemotherapy-induced cytoreduction in acute leukemia.
    Hiddemann W; Andreeff M; Clarkson BD
    Haematol Blood Transfus; 1981; 26():73-6. PubMed ID: 7319296
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of very high-dose thymidine infusions on leukemia and lymphoma patients.
    Blumenreich MS; Woodcock TM; Andreeff M; Hiddemann W; Chou TC; Vale K; O'Hehir M; Clarkson BD; Young CW
    Cancer Res; 1984 May; 44(5):2203-7. PubMed ID: 6713407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone marrow cell count per cubic millimeter bone marrow: a new parameter for quantitating therapy-induced cytoreduction in acute leukemia.
    Hiddemann W; Clarkson BD; Büchner T; Melamed MR; Andreeff M
    Blood; 1982 Feb; 59(2):216-25. PubMed ID: 7055637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A technique to quantify cytoreduction in the bone marrow induced by cytotoxic chemotherapy.
    Blumenreich MS; Strife A; Clarkson BD
    J Clin Oncol; 1983 Sep; 1(9):552-8. PubMed ID: 6668515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose thymidine infusions in patients with leukemia and lymphoma.
    Kufe DW; Beardsley P; Karp D; Parker L; Rosowsky A; Canellos G; Frei E
    Blood; 1980 Apr; 55(4):580-9. PubMed ID: 6965595
    [No Abstract]   [Full Text] [Related]  

  • 6. In vivo perturbation of human marrow cell cycle progression by ifosfamide.
    Rentschler RE; Barlogie B; Johnston DA; Bodey GP
    Cancer Res; 1978 Aug; 38(8):2209-15. PubMed ID: 667817
    [No Abstract]   [Full Text] [Related]  

  • 7. Sequential combination of methotrexate and vindesine in previously treated children with acute leukemia. A phase I-II study.
    Miller LP; Hancock C; Miller DR; Chello PL; Sirotnak FM; Tan CT
    Am J Clin Oncol; 1984 Oct; 7(5):465-70. PubMed ID: 6594925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of the H*1 in predicting marrow recovery following ablative chemotherapy in leukaemia and lymphoma.
    Kinsey SE; Carter AB; Watts MJ; Goldstone AH; Machin SJ
    Clin Lab Haematol; 1988; 10(1):1-5. PubMed ID: 3284693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of the significance of in vitro blast cell [3H]thymidine labelling indices obtained initially and serially during induction therapy of acute non-lymphocytic leukemia.
    Murphy SB; Dahl GV; George SL; Karas J; Look AT; Simone JV; Mauer AM
    Leuk Res; 1982; 6(5):639-48. PubMed ID: 7154706
    [No Abstract]   [Full Text] [Related]  

  • 10. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
    Early AP; Preisler HD; Slocum H; Rustum YM
    Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokinetics of human acute leukemia before and after chemotherapy.
    Sarna G; Omine M; Perry S
    Eur J Cancer (1965); 1975 Jul; 11(7):483-92. PubMed ID: 1059558
    [No Abstract]   [Full Text] [Related]  

  • 12. Management of patients with acute non-lymphocytic leukemia who fail first cycle of induction therapy.
    Hasbrouck DJ; Peterson BA; Hurd DD; Bloomfield CD
    Leuk Res; 1981; 5(4-5):357-61. PubMed ID: 7289645
    [No Abstract]   [Full Text] [Related]  

  • 13. Vindesine in the treatment of refractory hematologic malignancies: a phase II study.
    Mandelli F; Amadori S; Giona F; Antonietta M; Spiriti A; Pastore S; Meloni G; Paolucci G
    Leuk Res; 1982; 6(5):649-52. PubMed ID: 7154707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The effect of cytosine arabinoside on cell kinetics in adult acute leukemia and its correlation to the therapeutic response].
    Furusawa S; Adachi Y; Nomura T; Komiya M
    Rinsho Ketsueki; 1972 Dec; 13(6):943-50. PubMed ID: 4675065
    [No Abstract]   [Full Text] [Related]  

  • 15. [Methods of evaluating residual disease in bone marrow in malignant hemopathies. Prospectives].
    Hervé P; Favrot M
    Nouv Rev Fr Hematol (1978); 1987; 29(2):103-6. PubMed ID: 3302940
    [No Abstract]   [Full Text] [Related]  

  • 16. [Quantitative observation of leukemic cells and normal hematopoetic cells in the bone marrow during the treatment of acute leukemia (author's transl)].
    Oshima T
    Nihon Ketsueki Gakkai Zasshi; 1974 Apr; 37(2):73-92. PubMed ID: 4471882
    [No Abstract]   [Full Text] [Related]  

  • 17. [Phase II study of mitoxantrone for hematologic malignancies].
    Ueoka H; Ueno K; Yamane T; Toyoda K; Endo H; Nishihara R; Takahashi I; Ohnoshi T; Kitajima K; Kimura I
    Gan To Kagaku Ryoho; 1983 Nov; 10(11):2399-402. PubMed ID: 6639101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitoxantrone.
    Nathanson L
    Cancer Treat Rev; 1984 Dec; 11(4):289-93. PubMed ID: 6534511
    [No Abstract]   [Full Text] [Related]  

  • 19. Anthracycline-based therapy of de novo acute myeloid leukemia in adults: failure of first-cycle cytoreduction to predict second-cycle outcome.
    Hammerschmidt DE; Crea MT
    Am J Hematol; 1994 Nov; 47(3):172-7. PubMed ID: 7942780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antileukemic and immunosuppressive activity of 2-chloro-2'-deoxyadenosine.
    Carson DA; Wasson DB; Beutler E
    Proc Natl Acad Sci U S A; 1984 Apr; 81(7):2232-6. PubMed ID: 6585795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.